Söndag 22 December | 02:12:03 Europe / Stockholm
Svenska | English

Modulight

Kursutveckling under dagen för detta pressmeddelande (EUR).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2024-10-18 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-05-06 - X-dag ordinarie utdelning MODU 0.00 EUR
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-10-20 - 15-10 2023-Q3
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-03 - X-dag ordinarie utdelning MODU 0.00 EUR
2023-05-02 - Årsstämma
2023-04-28 - 15-10 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-03 - X-dag ordinarie utdelning MODU 0.00 EUR
2022-05-02 - Årsstämma

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Modulight är verksamt inom teknikbranschen. Bolaget designar, marknadsför och producerar biomedicinska laserprodukter som används inom onkologi, genetik och oftalmologi. Kunderna består primärt av sjukhus och företagskunder verksamma inom medicinteknik. Utöver huvudverksamheten erbjuds även diverse mervärdestjänster. Störst verksamhet återfinns inom Europa.
Modulight extends its quarterly reporting and updates its disclosure policy accordingly
2024-03-22 14:00:00

Modulight Corporation | Company Release | March 22, 2024 at 15:00:00 EET

Since its listing, Modulight Corporation has published, in addition to the half-yearly report and the financial statements release required by the rules of the Nasdaq Helsinki First North Growth Market Finland, slightly shorter voluntary three-month and nine-month business reviews.

Starting with the first quarter of 2024, Modulight extends its reporting further by publishing interim reports for January-March and January-September with the same details as the half-yearly reports and the financial statements releases. The change is the result of the development of reporting in line with Modulight’s targets.
Modulight has updated the company’s disclosure policy accordingly. The updated disclosure policy is available on the company’s web pages at https://modulight.com/governance/#disclosure-policy.

Financial reports publication schedule remains unchanged:

• 1Q24 Interim Report (1–3/2024) will be published on 26 April 2024
• 1H24 Half-year Financial Report (1–6/2024) will be published on 16 August 2024
• 3Q24 Interim Report (1–9/2024) will be published on 18 October 2024

For further information, please contact:

CEO Seppo Orsila, m. +358 40 830 4671

IR Ulla Haapanen, m. +358 40 830 4676
Email: ir@modulight.com

Certified adviser: Danske Bank A/S, Finland Branch, m. +358 40 414 5358
 
modulight.com
@modulight, @orsila

Modulight in brief

Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.

Follow Modulight: modulight.com | X | LinkedIn | Facebook | YouTube | Instagram | #killcancer #laserfamily

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden